Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Zhejiang Chinese Medical University · Zhejiang Lab · +6 more institutions
Abstract
Cancers are highly complex diseases that are characterized by not only the overgrowth of malignant cells but also an altered immune response. The inhibition and reprogramming of the immune system play critical roles in tumor initiation and progression. Immunotherapy aims to reactivate antitumor immune cells and overcome the immune escape mechanisms of tumors. Represented by immune checkpoint blockade and adoptive cell transfer, tumor immunotherapy has seen tremendous success in the clinic, with the capability to induce long-term regression of some tumors that are refractory to all other treatments. Among them, immune checkpoint blocking therapy, represented by PD-1/PD-L1 inhibitors (nivolumab) and CTLA-4…
Citation impact
- FWCI
- 43.99
- Percentile
- 100%
- References
- 530
Authors
3- DWDongrui WangCorresponding
Zhejiang Chinese Medical University, Zhejiang Lab, Zhejiang University-University of Edinburgh Institute, First Affiliated Hospital Zhejiang University, Zhejiang University
- XWXianlin Wu
Chinese Academy of Medical Sciences & Peking Union Medical College
- YSYingli Sun
Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Institute of Genomics, National Cancer Center
Topics & keywords
- Immunotherapy
- Nivolumab
- Medicine
- Ipilimumab
- Immune system
- Immune checkpoint
- Cancer immunotherapy
- Pembrolizumab
- Good health and well-being